References
- Forsgren L, Hesdorffer D. Epidemiology and prognosis of epilepsy. In: The Treatment of Epilepsy. Shorvon S, Perucca E, Engel J (Eds). Wiley-Blackwell, NJ, USA, 21–31 (2009).
- Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia34(3), 453–468 (1993).
- Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol.10(5), 446–456 (2011).
- Marson AG, Al-Kharusi AM, Alwaidh M et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet369(9566), 1000–1015 (2007).
- Brodie M, Barry SJ, Bamagous G, Norrie J, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Epilepsia52(Suppl. 6), 10 (2011).
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med.342(5), 314–319 (2000).
- Hermann B, Seidenberg M, Jones J. The neurobehavioural comorbidities of epilepsy: can a natural history be developed? Lancet Neurol.7(2), 151–160 (2008).
- Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case–control study. Lancet Neurol.6(8), 693–698 (2007).
- Tomson T, Nashef L, Ryvlin P. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol.7(11), 1021–1031 (2008).
- White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int. Rev. Neurobiol.81, 85–110 (2007).
- Pitkanen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol.10(2), 173–186 (2011).
- Mansbach H, Baulac M. Retigabine. In: The Treatment of Epilepsy. Shorvon S, Perucca E, Engel J (Eds). Wiley-Blackwell, NJ, USA, 637–646 (2009).
- Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol.58(2), 253–262 (2000).
- Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol.58(3), 591–600 (2000).
- Marrion NV. Control of M-current. Annu. Rev. Physiol.59, 483–504 (1997).
- Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat. Rev. Drug Discov.8(12), 982–1001 (2009).
- Singh NA, Charlier C, Stauffer D et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet.18(1), 25–29 (1998).
- Wang HS, Pan Z, Shi W et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science282(5395), 1890–1893 (1998).
- Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol. Pharmacol.67(4), 1009–1017 (2005).
- Rostock A, Tober C, Rundfeldt C et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res.23(3), 211–223 (1996).
- Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol.303(3), 163–169 (1996).
- Mazarati A, Wu J, Shin D, Kwon YS, Sankar R. Antiepileptogenic and anti-ictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study. Epilepsia49(10), 1777–1786 (2008).
- Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the ninth Eilat Conference (EILAT IX). Epilepsy Res.83(1), 1–43 (2009).
- Ferron GM, Paul J, Fruncillo R et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J. Clin. Pharmacol.42(2), 175–182 (2002).
- Ferron GM, Patat A, Parks V, Rolan P, Troy SM. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br. J. Clin. Pharmacol.56(1), 39–45 (2003).
- Hermann R, Knebel NG, Niebch G, Richards L, Borlak J, Locher M. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur. J. Clin. Pharmacol.58(12), 795–802 (2003).
- Hermann R, Ferron GM, Erb K et al. Effects of age and sex on the disposition of retigabine. Clin. Pharmacol. Ther.73(1), 61–70 (2003).
- Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology68(15), 1197–1204 (2007).
- Brodie MJ, Lerche H, Gil-Nagel A et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology75(20), 1817–1824 (2010).
- French JA, Abou-Khalil BW, Leroy RF et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology76(18), 1555–1563 (2011).
- Rheims S, Perucca E, Cucherat M, Ryvlin P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia52(2), 219–233 (2011).
- Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia48(7), 1303–1307 (2007).
- Burdette DE, Porter RJ, Lee WJK, Hall S, DeRossett SE. Long-term maintenance of efficacy with ezogabine (retigabine) 600–1200 mg/day: an assessment of three open-label extension studies over 12 months. Neurology76(9), A376–A377 (2011).
- Abou-Khalil B, Brodie M, Shaikh S, Lee WJK, Hall S, VanLandingham KE. Seizure-free rates in patients receiving long-term open-label ezogabine (retigabine) 600–1200 mg/day. Neurology76(9), A289–A289 (2011).
- Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann. Neurol.62(4), 382–389 (2007).
- Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anticonvulsant drug retigabine. J. Neurosci.21(15), 5535–5545 (2001).
- Brickel N, Hammond J, Viejo A, VanLandingham KE, Derossett SE. Cardiac safety and rates of sudden unexplained death in patients with partial-onset epilepsy treated with ezogabine (retigabine). Neurology76(9), A616–A616 (2011).
- Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia51(1), 7–26 (2010).
- Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol.10(11), 961–968 (2011).
- Ravizza T, Lucas SM, Balosso S et al. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. Epilepsia47(7), 1160–1168 (2006).
- Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia51(1), 27–36 (2010).
Website
- ClinicalTrials.gov. An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation. http://clinicaltrials.gov/ct2/show/NCT01332513?term=retigabine&rank=3